Aidan J Murphy, Alexandria G O'Neal, Ronald A Cohen, Damon G Lamb, Eric C Porges, Sarah A Bottari, Brian Ho, Erin Trifilio, Steven T DeKosky, Kenneth M Heilman, John B Williamson
Better treatments are needed to improve cognition and brain health in people with mild cognitive impairment (MCI) and Alzheimer's disease (AD). Transcutaneous vagus nerve stimulation (tVNS) may impact brain networks relevant to AD through multiple mechanisms including, but not limited to, projection to the locus coeruleus, the brain's primary source of norepinephrine, and reduction in inflammation. Neuropathological data suggest that the locus coeruleus may be an early site of tau pathology in AD. Thus, tVNS may modify the activity of networks that are impaired and progressively deteriorate in patients with MCI and AD...
December 7, 2022: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics